Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity.
about
Interactions of iprindole with fenfluramine metabolism in rat brain and liverSerotonergic drugs and valvular heart diseaseEvidence that mCPP may have behavioural effects mediated by central 5-HT1C receptorsPrimary pulmonary hypertension and fenfluramine useThe effects of fenfluramine on in vitro platelet aggregationA 5-hydroxytryptamine-like mode of anorectic action for 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212)Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trialFrom galactorrhea to osteopenia: rethinking serotonin-prolactin interactions.Hypothalamic Ahi1 mediates feeding behavior through interaction with 5-HT2C receptor.Psychoactive drugs and human sexual behavior: the role of serotonergic activity.The regulation of food intake by the gut-brain axis: implications for obesity.Functional foods as potential therapeutic options for metabolic syndrome.Epidemiology of Obesity and Pharmacologic Treatment Options.The effect of fenfluramine on the microstructure of feeding and drinking in the rat.Fluoxetine: adverse effects and drug-drug interactions.Insulin resistance in systemic hypertension: pharmacotherapeutic implications.Influence of a combination of herbs on appetite suppression and weight loss in rats.Interaction between the serotonergic, dopaminergic, and glutamatergic systems in fenfluramine-induced Fos expression in striatal neurons.Information processing in anxiety: a pilot study of the effect of manipulating 5-HT function.A Review on Pharmacological Properties of Zingerone (4-(4-Hydroxy-3-methoxyphenyl)-2-butanone)
P2860
Q24535627-526FF65A-5EEB-4111-B70E-7FA766708A19Q24646869-B3F878B4-0F48-4EB1-966F-0F26E305A541Q24681893-1A4D834A-581A-481B-AA25-324580C7EB6BQ28378428-345FC951-1A8B-4691-A6E6-8B747408066CQ34511905-A73CAD39-4FEF-4ADF-BC18-1746C595DAE4Q35177369-34B08144-557A-4307-A0AF-0496A2BB857DQ35625284-CBFCE225-3FEB-4348-B1B3-3E6C9DA98E7FQ35680852-F8FD454A-D805-415B-8DBB-EFCBD6EE7105Q35694089-A21FE66B-8C31-45C2-B9A3-95E5CD7F0D6FQ36272836-CC53EF57-8357-401E-B5F4-9032CA2BB93EQ38019805-FEF8D9F0-91D9-45D5-9086-10E3206783D5Q38582214-888A7571-4D89-45A2-8475-5A3EFDBD1735Q38717129-789EC171-C640-4D17-BC89-F3CEBA8CAB72Q39927467-1840FA2F-001E-40F1-9E32-62DD85A0CB15Q40787276-81E2E211-7CBF-4AC5-8A16-80A271A28519Q40949586-9F935669-612F-431F-B31A-C7A0E4FCDFA2Q43644870-4B197A50-9B0B-4C8F-A291-F7D05A875017Q48574615-408CD590-F218-4995-AC9E-903A3E532DE4Q52185495-1EA5AAC0-9D71-442C-8ECA-59A19377C2F2Q59121326-0224B3D6-922A-4F66-84B2-3887672F65B7
P2860
Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity.
description
1975 nî lūn-bûn
@nan
1975年の論文
@ja
1975年論文
@yue
1975年論文
@zh-hant
1975年論文
@zh-hk
1975年論文
@zh-mo
1975年論文
@zh-tw
1975年论文
@wuu
1975年论文
@zh
1975年论文
@zh-cn
name
Fenfluramine: a review of its ...... erapeutic efficacy in obesity.
@en
type
label
Fenfluramine: a review of its ...... erapeutic efficacy in obesity.
@en
prefLabel
Fenfluramine: a review of its ...... erapeutic efficacy in obesity.
@en
P2093
P1433
P1476
Fenfluramine: a review of its ...... erapeutic efficacy in obesity.
@en
P2093
P R Sawyer
R M Pinder
T M Speight
P304
P356
10.2165/00003495-197510040-00001
P577
1975-01-01T00:00:00Z
P6179
1023041857